AnHeart Therapeutics
Dawn Spooner is an experienced professional in regulatory affairs, currently serving as Senior Director of Regulatory Affairs at AnHeart Therapeutics. Previously, Spooner held the position of Senior Director of Global Regulatory Strategy at EQRx from December 2020 to July 2022. Additional experience includes roles as Senior Director of Regulatory Affairs at Boston Pharmaceuticals and as Regulatory Affairs specialist at BD, focusing on Interventional Surgery. Spooner has also worked as Director of Regulatory Affairs at Summit Therapeutics plc, Associate Director of Regulatory Affairs at PerkinElmer, Senior Manager of Regulatory Affairs CMC at Cubist Pharmaceuticals, and as Regulatory Affairs Manager at Bristol-Myers Squibb Medical Imaging.
AnHeart Therapeutics
AnHeart Therapeutics (“AnHeart”) is a clinical-stage global biopharmaceutical company developing a broad pipeline of novel precision oncology therapeutics with high unmet medical needs. Its lead asset, taletrectinib, is a potential best-in-class next-generation ROS1 inhibitor currently in Phase 2 trials for ROS1 TKI-naïve and TKI-pretreated patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC). Taletrectinib has received Breakthrough Therapy Designation (BTD) from both the US FDA and China NMPA for the treatment of patients with advanced or metastatic ROS1+ NSCLC, who are either ROS1 TKI treatment naïve or previously treated with crizotinib. The Company’s pipeline also includes AB-218, a mIDH1 inhibitor in Phase 2 trials with good brain penetration for multiple solid tumors with mIDH1 mutations and AB-329, an AXL inhibitor in Phase 1 studies to be used in combination with checkpoint inhibitor or chemotherapies in NSCLC or other solid tumors. The Company operates from offices in the US and China.